Andreas G Moraitis
Overview
Explore the profile of Andreas G Moraitis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DeFronzo R, Auchus R, Bancos I, Blonde L, Busch R, Buse J, et al.
BMJ Open
. 2024 Jul;
14(7):e081121.
PMID: 39013654
Introduction: Even with recent treatment advances, type 2 diabetes (T2D) remains poorly controlled for many patients, despite the best efforts to adhere to therapies and lifestyle modifications. Although estimates vary,...
2.
Donegan D, Pivonello R, Stigliano A, Lardo P, Kearney T, Mezosi E, et al.
Endocr Pract
. 2023 Oct;
30(1):11-18.
PMID: 37805100
Objective: To assess the effect of relacorilant, a selective glucocorticoid receptor modulator under investigation for the treatment of patients with endogenous hypercortisolism (Cushing syndrome [CS]), on the heart rate-corrected QT...
3.
Mallick S, Chakrabarti J, Eschbacher J, Moraitis A, Greenstein A, Churko J, et al.
Transl Res
. 2023 Jan;
256:56-72.
PMID: 36640905
Cushing's disease (CD) is a serious endocrine disorder attributed to an adrenocorticotropic hormone (ACTH)-secreting pituitary neuroendocrine tumor (PitNET) that that subsequently leads to chronic hypercortisolemia. PitNET regression has been reported...
4.
Pivonello R, Bancos I, Feelders R, Kargi A, Kerr J, Gordon M, et al.
Front Endocrinol (Lausanne)
. 2022 May;
13:899616.
PMID: 35574017
[This corrects the article DOI: 10.3389/fendo.2021.662865.].
5.
Parker J, Moraitis A, Belanoff J
AACE Clin Case Rep
. 2022 Jan;
8(1):25-29.
PMID: 35097198
Background: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder in Western industrialized countries and may progress to liver injury. Cortisol is thought to play a role in...
6.
Pivonello R, Munster P, Terzolo M, Ferrigno R, Simeoli C, Puglisi S, et al.
Front Endocrinol (Lausanne)
. 2022 Jan;
12:793262.
PMID: 35058882
Somatostatin exhibits an inhibitory effect on pituitary hormone secretion, including inhibition of growth hormone and adrenocorticotropic hormone (ACTH), and it can have antisecretory and antitumor effects on neuroendocrine tumors (NETs)...
7.
Pivonello R, Bancos I, Feelders R, Kargi A, Kerr J, Gordon M, et al.
Front Endocrinol (Lausanne)
. 2021 Aug;
12:662865.
PMID: 34335465
Introduction/purpose: Relacorilant is a selective glucocorticoid receptor modulator (SGRM) with no progesterone receptor activity. We evaluated the efficacy and safety of relacorilant in patients with endogenous Cushing syndrome (CS). Materials...
8.
Bancos I, Hatipoglu B, Yuen K, Chandramohan L, Chaudhari S, Moraitis A
J Clin Transl Endocrinol
. 2021 Jul;
24:100256.
PMID: 34258233
Purpose: To evaluate the performance of FKBP5 as a cortisol activity biomarker in patients with ACTH-dependent Cushing syndrome (CS). Methods: This was a prospective, multicenter, nonrandomized, noninterventional study of a...
9.
Ragucci E, Nguyen D, Lamerson M, Moraitis A
Case Rep Endocrinol
. 2018 Jan;
2017:6161348.
PMID: 29348947
Cushing syndrome (CS), a complex, multisystemic condition resulting from prolonged exposure to cortisol, is frequently associated with nonalcoholic fatty liver disease (NAFLD). In patients with adrenal adenoma(s) and NAFLD, it...
10.
Yau H, Kinaan M, Quinn S, Moraitis A
Biologics
. 2017 Dec;
11:115-122.
PMID: 29255345
Over the past three decades, the incidence and prevalence of neuroendocrine tumors have gradually increased. Due to the slow-growing nature of these tumors, most cases are diagnosed at advanced stages....